2020
DOI: 10.1007/s00432-020-03251-5
|View full text |Cite
|
Sign up to set email alerts
|

Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
10
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 12 publications
(10 citation statements)
references
References 25 publications
0
10
0
Order By: Relevance
“…Camrelizumab is one of the most widely used anti-PD-1 antibodies for various solid tumors in real-time practice owing to drug accessibility and economic pressure for patients in China. It has shown promising clinical efficacy in several kinds of solid tumors, based on positive efficacy results in clinical trials ( 8 11 ), and has also been shown to be effective in MSI-H/dMMR solid tumors ( 12 ). The combination of regorafenib and camrelizumab achieved an ORR of 25% in 16 patients with MSS refractory mCRC, indicating the potential benefit of immunotherapy under an appropriately combined therapeutic strategy ( 13 ).…”
Section: Introductionmentioning
confidence: 99%
“…Camrelizumab is one of the most widely used anti-PD-1 antibodies for various solid tumors in real-time practice owing to drug accessibility and economic pressure for patients in China. It has shown promising clinical efficacy in several kinds of solid tumors, based on positive efficacy results in clinical trials ( 8 11 ), and has also been shown to be effective in MSI-H/dMMR solid tumors ( 12 ). The combination of regorafenib and camrelizumab achieved an ORR of 25% in 16 patients with MSS refractory mCRC, indicating the potential benefit of immunotherapy under an appropriately combined therapeutic strategy ( 13 ).…”
Section: Introductionmentioning
confidence: 99%
“…It has been approved by CFDA for the treatment of advanced non-small-cell lung cancer, advanced hepatic cancer, advanced esophageal cancer, and classic Hodgkin's lymphoma. Camrelizumab was also proved to have efficacy in MSI-H/dMMR advanced or metastatic colorectal cancer in a study with a small sample size [12]. However, the clinical benefit of camrelizumab to the therapy of MSS/pMMR mCRC has not yet been reported.…”
mentioning
confidence: 99%
“…In clinical trials of camrelizumab in advanced solid tumors, some bladder carcinoma patients got a complete response[ 6 ]. Camrelizumab provided improved ORR and DCR in pre-treated patients with dMMR/MSI-H and advanced or metastatic solid tumor[ 7 , 8 ]. With the increase of approved immune checkpoint inhibitors, it is urgent to define patient subgroups that are more likely to have treatment benefits.…”
Section: Discussionmentioning
confidence: 99%